EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+17.74%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.94B
AUM Growth
+$3.94B
(+2.3%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-3.48%
Top 10 Holdings %
Top 10 Hldgs %
61.38%
Holding
66
New
15
Increased
8
Reduced
4
Closed
9
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$141M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$100M |
| 3 |
CRISPR Therapeutics
CRSP
|
$94.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$76.5M |
| 5 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$43.3M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$435M |
| 2 |
LENZ
LENZ Therapeutics
LENZ
|
$163M |
| 3 |
argenx
ARGX
|
$115M |
| 4 |
Edgewise Therapeutics
EWTX
|
$40.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$19.1M |
Sector Composition
| 1 | Healthcare | 99.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $668M | 16.89% | 11,357,425 +184,357 | +2% | +$10.8M |
|
2
Prothena Corp
PRTA
$441M
| $287M | 7.26% | 11,584,280 | – | – |
|
3
Arvinas
ARVN
$568M
| $278M | 7.02% | 6,726,491 | – | – |
|
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $249M | 6.29% | 1,919,835 +1,086,928 | +130% | +$141M |
|
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $195M | 4.92% | 4,155,375 +2,142,858 | +106% | +$100M |
|
6
Galapagos
GLPG
$2.07B
| $185M | 4.69% | 5,756,268 | – | – |
|
7
AnaptysBio
ANAB
$569M
| $169M | 4.28% | 7,521,024 | – | – |
|
8
Zymeworks
ZYME
$1.12B
| $141M | 3.58% | 13,437,473 | – | – |
|
9
Kura Oncology
KURA
$686M
| $124M | 3.13% | 5,806,871 | – | – |
|
10
Jazz Pharmaceuticals
JAZZ
$7.75B
| $122M | 3.09% | 1,013,952 | – | – |
|
11
Xencor
XNCR
$580M
| $118M | 2.98% | 5,330,416 +47,900 | +0.9% | +$1.06M |
|
12
Acadia Pharmaceuticals
ACAD
$4.38B
| $111M | 2.8% | 5,991,479 | – | – |
|
13
Tango Therapeutics
TNGX
$747M
| $106M | 2.68% | 13,330,736 | – | – |
|
14
Immunome
IMNM
$828M
| $95.7M | 2.42% | 3,879,415 | – | – |
|
|
15
CRISPR Therapeutics
CRSP
$4.71B
| $94.7M | 2.4% | +1,389,276 | New | +$94.7M |
|
16
Mersana Therapeutics
MRSN
$36.5M
| $86.8M | 2.19% | 19,364,688 | – | – |
|
|
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $83.9M | 2.12% | 2,384,384 +2,173,122 | +1,029% | +$76.5M |
|
18
Nuvation Bio
NUVB
$1.02B
| $69.9M | 1.77% | 19,209,643 | – | – |
|
19
Neurogene
NGNE
$264M
| $64.7M | 1.64% | 1,271,342 | – | – |
|
|
CNTA
20
Centessa Pharmaceuticals
CNTA
$2.25B
| $63.5M | 1.61% | 5,618,779 | – | – |
|
21
Oric Pharmaceuticals
ORIC
$994M
| $47M | 1.19% | 3,418,068 | – | – |
|
|
ADAP
22
Adaptimmune Therapeutics
ADAP
$15.6M
| $43.3M | 1.1% | +27,404,070 | New | +$43.3M |
|
23
TScan Therapeutics
TCRX
$102M
| $39.7M | 1% | 5,000,000 | – | – |
|
24
Voyager Therapeutics
VYGR
$186M
| $36.5M | 0.92% | 3,917,546 +66,039 | +2% | +$615K |
|
|
THRD
25
DELISTED
Third Harmonic Bio
THRD
| $30M | 0.76% | 3,182,444 | – | – |
|